ArticleParasites & vectors2020
Efficacy of orally and topically administered fluralaner (Bravecto
Article in Parasites & vectors, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 1 synthesis or guideline pooled it, 30 citations in OpenAlex.
- A systematic review of fluralaner as a treatment for ectoparasitic infections in mammalian species.PeerJ · 2025Pooled it
- Efficacy of a fluralaner-based ectoparasiticide for the control of otodectic and sarcoptic mange in naturally infested dogs, evaluated in randomized, double-blind clinical studies.Parasites & vectors · 2026Article
- The safety and efficacy of topical clove oil for the treatment of naturally occurringFrontiers in veterinary science · 2026Article
- Field efficacy assessment of a combination of afoxolaner, moxidectin and pyrantel pamoate to treat dogs naturally infested with Sarcoptes scabiei.Parasite (Paris, France) · 2026Article
- Restorative potential of melatonin during treatment of severe scabies in an experimental model.Parasitology research · 2025Article
- Functional and sequence-based comparison of Ctenocephalides felis and Rhipicephalus sanguineus sensu lato isolates from different geographic regions.Parasites & vectors · 2025Article
- Effective treatment of sarcoptic mange in an alpaca (Vicugna pacos) using fluralaner: a case report.Veterinary research communications · 2024Article
- Eliminate all risks: A call to reexamine the link between canine scabies and rheumatic heart disease.PLoS neglected tropical diseases · 2024Article
- Efficacy of monthly treatment with oral fluralaner (BravectoParasites & vectors · 2024Article
- Control of Rhipicephalus microplus on taurine cattle with fluralaner in a subtropical region.Parasites & vectors · 2024Article
- Successful treatment of 3 naturally acquired cases of canine cheyletiellosis with fluralaner.The Canadian veterinary journal = La revue veterinaire canadienne · 2024Article
- Two protocols using fluralaner for Rhipicephalus microplus strategic control on taurine cattle in a tropical region.Parasites & vectors · 2024Article
- Prevalence, clinical presentation, and therapeutic outcome of ectoparasitic infestations in dogs in Egypt.Open veterinary journal · 2023Article
- Efficacy of a chewable tablet containing sarolaner, moxidectin, and pyrantel (Simparica TrioParasites & vectors · 2023Article
- Efficacy of fluralaner chewable tablets (BravectoParasites & vectors · 2023Article
- Isoxazolines for treating canine demodicosis, sarcoptic mange (scabies), and lice infestation.The Canadian veterinary journal = La revue veterinaire canadienne · 2022Article
- Zoonotic Episodes of Scabies: A Global Overview.Pathogens (Basel, Switzerland) · 2022Review
- The application, value, and impact of outcomes research in animal health and veterinary medicine.Frontiers in veterinary science · 2022Article
- Review
- Recent advances in understanding and treating scabies.Faculty reviews · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSuccessful canine sarcoptic mange treatment requires immediate efficacy to eliminate active mites, and sustained activity to prevent re-infestation from in-contact animals and fomites. With extended acaricidal activity, fluralaner has been shown to be effective for treating this disease. To confirm this potential under field conditions, two fluralaner formulations were administered to mite-infested, client-owned dogs.
methodsHouseholds qualified for inclusion if they had at least one dog positive for Sarcoptes scabiei mites, confirmed by skin scraping, and at least one dog with clinical signs evocative of sarcoptic mange. Households were allocated to groups of dogs to receive a single treatment with either oral (Bravecto
resultsThere were 98 participating households and 135 dogs enrolled across Albania, France, Italy and Portugal. On Day 28, more than 90% of dogs in each group were negative for mites. On Days 56 and 84, all study dogs were free of mites and most dermatological signs of sarcoptic mange had resolved. There were no treatment-related adverse events in any group.
conclusionsA single treatment of client-owned, sarcoptic mange-affected dogs with either fluralaner chewable tablets or fluralaner spot-on formulation proved a safe and effective treatment of infestations with S. scabiei var. canis, maintained through 84 days (12 weeks) after treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.